Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel

Daniel M. Weinberger, Noga Givon-Lavi, Yonat Shemer-Avni, Jacob Bar-Ziv, Wladimir J. Alonso, David Greenberg, Ron Dagan

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Postlicensure surveillance of pneumonia incidence can be used to estimate whether pneumococcal conjugate vaccines (PCVs) affect incidenceWe used Poisson regression models that control for baseline seasonality to determine the impact of PCVs and the possible effects of variations in virus activity in Israel on these surveillance estimatesPCV was associated with significant declines in radiologically confirmed alveolar pneumonia (RCAP) among patients <6 months, 6-17 months, and 18-35 months of age (-31% [95% CI-51% to-15%],-41% [95% CI-52 to-32%], and-34% [95% CI-42% to-25%], respectively)Respiratory syncytial virus (RSV) activity was associated with strong increases in RCAP incidence, with up to 44% of cases attributable to RSV among infants <6 months of age and lower but significant impacts in older childrenSeasonal variations, particularly in RSV activity, masked the impact of 7-valent PCVs, especially for young children in the first 2 years after vaccine introduction.

Original languageEnglish
Pages (from-to)1084-1091
Number of pages8
JournalEmerging Infectious Diseases
Issue number7
StatePublished - 1 Jul 2013

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel'. Together they form a unique fingerprint.

Cite this